I'm sure potential partners are taking a look, just the same as they always were. But it doesn't mean it's the best fit for ANP and shareholders at this stage in progression and I don't think it could extract value anything like what a partnership could do, either during or post 1102 DMD trial. But in what capacity do you mean exactly. It's easy to say but harder to define. Let me know your vision ?
Ann: US FDA Type C Meeting for ATL1102 in DMD, page-44
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
